You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 9,717,750

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,717,750 protect, and when does it expire?

Patent 9,717,750 protects SPINRAZA and is included in one NDA.

This patent has sixty-three patent family members in twenty-three countries.

Summary for Patent: 9,717,750

Patent landscape, scope, and claims:

Title:	Compositions and methods for modulation of SMN2 splicing in a subject
Abstract:	Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
Inventor(s):	Bennett; C. Frank (Carlsbad, CA), Hung; Gene (San Diego, CA), Rigo; Frank (Carlsbad, CA), Krainer; Adrian R. (Huntington Square, NY), Hua; Yimin (Jericho, NY), Passini; Marco A. (Shrewsbury, MA), Shihabuddin; Lamya (Brighton, MA), Cheng; Seng H. (Natick, MA), Klinger; Katherine W. (Sudbury, MA)
Assignee:	Biogen MA Inc. (Cambridge, MA) Cold Spring Harbor Laboratory (Cold Spring Harbor, NY)
Application Number:	14/617,388
Patent Claim Types: see list of patent claims	Use;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 9,717,750

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Biogen Idec	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				TREATMENT OF SPINAL MUSCULAR ATROPHY BY INCREASING EXON-7 INCLUSION IN SMN2 MRNA	⤷ Subscribe
Biogen Idec	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				TREATMENT OF TYPE III SPINAL MUSCULAR ATROPHY	⤷ Subscribe
Biogen Idec	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				TREATMENT OF TYPE II SPINAL MUSCULAR ATROPHY	⤷ Subscribe
Biogen Idec	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				TREATMENT OF SPINAL MUSCULAR ATROPHY	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,717,750

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3449926	⤷ Subscribe	2020008	Norway	⤷ Subscribe
Australia	2010262862	⤷ Subscribe
Australia	2016200344	⤷ Subscribe
Canada	2765396	⤷ Subscribe
China	102665731	⤷ Subscribe
China	106983768	⤷ Subscribe
China	115227709	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.